Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Equity Average (2021 - 2025)

Historic Equity Average for Barinthus Biotherapeutics (BRNS) over the last 5 years, with Q3 2025 value amounting to $93.5 million.

  • Barinthus Biotherapeutics' Equity Average fell 4085.65% to $93.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.5 million, marking a year-over-year decrease of 4085.65%. This contributed to the annual value of $158.6 million for FY2024, which is 2628.24% down from last year.
  • Barinthus Biotherapeutics' Equity Average amounted to $93.5 million in Q3 2025, which was down 4085.65% from $109.0 million recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Equity Average peaked at $254.0 million during Q2 2022, and registered a low of -$44.9 million during Q1 2021.
  • Over the past 5 years, Barinthus Biotherapeutics' median Equity Average value was $191.3 million (recorded in 2023), while the average stood at $178.0 million.
  • As far as peak fluctuations go, Barinthus Biotherapeutics' Equity Average soared by 66349.69% in 2022, and later plummeted by 4085.65% in 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Equity Average (Quarter) stood at $247.5 million in 2021, then decreased by 1.55% to $243.7 million in 2022, then fell by 21.49% to $191.3 million in 2023, then dropped by 24.31% to $144.8 million in 2024, then plummeted by 35.41% to $93.5 million in 2025.
  • Its Equity Average was $93.5 million in Q3 2025, compared to $109.0 million in Q2 2025 and $122.9 million in Q1 2025.